FDA “Failure” To Approve Generic Biologics Questioned By Commerce Cmte.
Executive Summary
The House Energy and Commerce Committee appears to be gearing up to create legislation establishing a pathway for the approval of follow-on biologics
You may also be interested in...
Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
Legislation to create a pathway for FDA approval of generic biologics should be attached to the reauthorization of the Prescription Drug User Fee Act, Sen. Charles Schumer, D-N.Y., said at a Feb. 14 press conference announcing reintroduction of the bill
Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
Legislation to create a pathway for FDA approval of generic biologics should be attached to the reauthorization of the Prescription Drug User Fee Act, Sen. Charles Schumer, D-N.Y., said at a Feb. 14 press conference announcing reintroduction of the bill
BIO CEO Greenwood In A Conversation With “The Pink Sheet”
Biotechnology Industry Organization President and CEO Jim Greenwood reflects on the trade group's legislative priorities in 2007 as the new Democratic-controlled Congress gets to work. Greenwood joined BIO in January 2005 after 12 years in Congress as a Republican Representative from the 8 district of Pennsylvania. In Congress, he served as chairman of the Energy and Commerce Committees Subcommittee on Oversight and Investigations, where he led a review of drug reimbursement issues and contributed to the passage of the Medicare Modernization Act of 2003.